Vaxart controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile2 entries
2021
Stockholder derivative litigation over alleged insider trading
Shareholders filed a Delaware Court of Chancery action alleging that Vaxart executives breached fiduciary duties and engaged in insider trading connected with statements about the company’s vaccine work. The case was dismissed in early 2024, according to the supplied reference material.
2020
Securities litigation concerning Operation Warp Speed statements
A federal securities class action alleged that investors were misled about Vaxart’s involvement in Operation Warp Speed. The supplied material states that the class was certified in December 2024 and that Vaxart was dismissed from the case later that year. The company denied the allegations.